Too scared to speak in public? Biohaven says it has a drug that can helpAllbiopro2018-08-17T01:13:42+09:008월 17th, 2018|
Duke antidepressant startup Evecxia brings on ex-Cerecor chief as CEOAllbiopro2018-08-17T01:13:15+09:008월 17th, 2018|
Regeneron, Teva’s pain drug clears phase 3 efficacy barAllbiopro2018-08-17T01:12:48+09:008월 17th, 2018|
Jazz scales back Erwinaze push due to manufacturing disruptionsAllbiopro2018-08-17T01:12:22+09:008월 17th, 2018|
Ex-Shire director to aid Catalent’s shift to commercial manufacturingAllbiopro2018-08-17T01:11:54+09:008월 17th, 2018|
‘Building up’ stretchable electronics to be as multipurpose as your smartphoneAllbiopro2018-08-17T01:11:02+09:008월 17th, 2018|
An effective approach to optimizing medicinal moleculesAllbiopro2018-08-17T01:10:32+09:008월 17th, 2018|
PhRMA Releases Annual Survey, Shows Highest R&D Spending EverAllbiopro2018-08-16T01:28:48+09:008월 16th, 2018|
J&J Reports Positive Phase III Data for its Two-Drug HIV ComboAllbiopro2018-08-16T01:28:21+09:008월 16th, 2018|
Express Scripts Eyes Expanding Coverage of Million Dollar-Plus Gene TherapiesAllbiopro2018-08-16T01:27:03+09:008월 16th, 2018|
As EpiPens run short, Kaléo boasts it has an available supply of epinephrine injectorsAllbiopro2018-08-16T01:26:10+09:008월 16th, 2018|
GlaxoSmithKline scores new win for 2-drug HIV regimen, this time in long-acting versionAllbiopro2018-08-16T01:25:41+09:008월 16th, 2018|
